LintonPharm to release data on Catumaxomab at ASCO meeting
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Subscribe To Our Newsletter & Stay Updated